Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Total patient population screened

From: Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada

(A)Number of Breast Cancer Cases in Families
  Total 5 BC in family 4 BC in family 3 BC in family 2 BC in family 1 BC in family 0 BC in family
Female Unilateral Breast 126 19 25 31 39 12 0
Female Multiple Primary Breast 24 1 4 2 12 5 0
Male Breast 12 0 0 1 4 7 0
Breast and Ovarian 4 1 1 0 1 1 0
Ovarian 9 0 2 2 2 1 2
Total screened 175 21 32 36 58 26 2
PALB2 mutations* 2 0 0 2 0 0 0
B) Proximity to Breast Cancer Cases in Families
  Total FDR with BC SDR with BC TDR with BC No relatives with BC
Female Unilateral Breast 126 79 28 7 12
Female Multiple Primary Breast 24 11 5 3 5
Male Breast 12 2 1 2 7
Breast and Ovarian 4 2 0 1 1
Ovarian 9 4 2 1 2
Total screened 175 98 36 14 27
PALB2 mutations* 2 1 0 1 0
  1. *Only the two definitely deleterious mutations were included in these tables. BC = breast cancer; FDR = first degree relative; SDR = second degree relative; TDR = third degree relative.